Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Drops By 25.4%

Vivani Medical, Inc. (NASDAQ:VANI) was the target of a significant decline in short interest in February. As of February 27th, there was short interest totaling 290,597 shares, a decline of 25.4% from the February 12th total of 389,363 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average daily trading volume, of 201,565 shares, the days-to-cover ratio is presently 1.4 days. Based on an average daily trading volume, of 201,565 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.7% of the company’s shares are short sold.

Insider Activity at Vivani Medical

In other news, Director Gregg Williams acquired 1,351,351 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was acquired at an average price of $1.48 per share, with a total value of $1,999,999.48. Following the completion of the transaction, the director directly owned 27,915,460 shares in the company, valued at approximately $41,314,880.80. This represents a 5.09% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have bought 4,826,881 shares of company stock worth $5,962,104 in the last ninety days. Insiders own 46.40% of the company’s stock.

Institutional Investors Weigh In On Vivani Medical

Several hedge funds have recently modified their holdings of the stock. Tudor Investment Corp ET AL purchased a new stake in Vivani Medical in the fourth quarter valued at approximately $1,127,000. Marshall Wace LLP acquired a new position in Vivani Medical during the fourth quarter worth approximately $174,000. State Street Corp raised its stake in Vivani Medical by 12.5% during the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after purchasing an additional 16,070 shares during the period. Jane Street Group LLC acquired a new position in shares of Vivani Medical in the 4th quarter valued at $60,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares during the last quarter. 6.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VANI has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Vivani Medical to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.00.

Vivani Medical Price Performance

VANI opened at $1.10 on Friday. The stock has a market capitalization of $85.99 million, a price-to-earnings ratio of -2.44 and a beta of 3.17. The business has a 50-day moving average of $1.28 and a two-hundred day moving average of $1.36. Vivani Medical has a 12 month low of $0.91 and a 12 month high of $1.92.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.